Quantcast

Latest Pulmonology Stories

2014-09-21 23:00:17

LifeScienceIndustryResearch.com adds “Pulmicort (Asthma) – Forecast and Market Analysis to 2023” to its store. Detailed information on Pulmicort including product description, safety and efficacy profiles as well as a SWOT analysis. Dallas, Texas (PRWEB) September 22, 2014 AstraZeneca’s Pulmicort is an ICS therapy that was originally launched in 1997, and is used prophylactically for the maintenance treatment of asthma in children and adults. Its active ingredient, budesonide, is...

2014-09-20 23:02:18

LifeScienceIndustryResearch.com adds “Symbicort (Asthma) - Forecast and Market Analysis to 2023” to its store. Report provides Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Dallas, TX (PRWEB) September 20, 2014 New PharmaPoint Drug Evaluation report, “Symbicort (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious...

2014-09-19 08:26:05

DALLAS, September 19, 2014 /PRNewswire/ -- RnRMarketResearch.com adds asthma drugs market research reports titled "Asthma - Japan Drug Forecast and Market Analysis to 2023", "Asthma - US Drug Forecast and Market Analysis to 2023" and "Asthma - 5EU Drug Forecast and Market Analysis to 2023" to its online library. According to Asthma - 5EU Drug Forecast and Market Analysis to 2023...

2014-09-15 20:21:53

MarketOptimizer.org adds new report "EpiCast Report: Asthma - Epidemiology Forecast to 2023" to its store. In 2013, there were 137.66 million lifetime prevalent cases of asthma in the 10MM, with 82.71 million cases in the US (43.16 million cases) and India (39.55 million cases) combined. DALLAS, Sept. 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term condition...

2014-09-11 04:21:18

OXFORD, England, September 11, 2014 /PRNewswire/ -- Successful Completion of Biomedical Catalyst Programme Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that it has confirmed the potential of its Multi-component Particle(TM) (MCP(TM)) Technology for creating novel inhaled, dual and triple fixed dose combination (FDC) therapies for respiratory diseases. The Company...

2014-09-10 12:24:27

RIDGEFIELD, Conn., Sept. 10, 2014 /PRNewswire/ -- In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Pharmaceuticals, Inc., announces the airing of Every Breath Counts: Idiopathic Pulmonary Fibrosis -- a documentary supported by the company and created in collaboration with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis in an effort to increase awareness and understanding of idiopathic pulmonary fibrosis (IPF) among the general public....

Schools Without Health Plans Unprepared To Handle Life-threatening Emergencies
2014-09-10 03:15:17

By Marla Paul, Northwestern University Only one in four students with asthma and half of children with food allergies have emergency health management plans in place at school, leaving schools inadequately prepared to manage daily needs and handle medical emergencies related to often life-threatening medical conditions, reports a new Northwestern Medicine study in partnership with Chicago Public Schools (CPS). "Given the amount of time kids spend in school, it's critical for school...

2014-09-09 12:28:55

Breathe NIOV System Also Wins European Respiratory Society POINT Award IRVINE, Calif., Sept. 9, 2014 /PRNewswire/ -- Breathe Technologies, a developer and manufacturer of innovative medical technologies for patients with respiratory insufficiency diseases and neuromuscular diseases, announced today that it received CE Certification for its Non-Invasive Open Ventilation (NIOV) System, enabling the company to market and sell the device in the European Union. In addition, the NIOV...

2014-09-09 08:32:06

For U.S. Media Only RIDGEFIELD, Conn., Sept. 9, 2014 /PRNewswire/ -- A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS(TM) trials, presented today at the European Respiratory Society International Congress (ERS) evaluated the impact of the investigational drug nintedanib on reducing the decline in lung function, as measured by annual rate of decline in forced vital capacity (FVC), in patients with idiopathic pulmonary fibrosis (IPF)...

2014-09-08 12:30:18

Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD, Conn., Sept. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented the first data from the pivotal Phase III TONADO(TM) 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium plus olodaterol delivered via the Respimat(®) inhaler in patients with moderate to...


Latest Pulmonology Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »
Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin